Dacarbazine

220px
Dacarbazine
Systematic (IUPAC) name
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
Identifiers
CAS number	4342-03-4
ATC code	L01AX04
PubChem	2942
DrugBank	APRD00331
Chemical data
Formula	C6H10N6O
Mol. mass	182.18
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	5 hours
Excretion	40% renal (unchanged)
Therapeutic considerations
Pregnancy cat.	C
Legal status	℞ Prescription only
Routes	IV

WikiDoc Resources for Dacarbazine
Articles
Most recent articles on Dacarbazine Most cited articles on Dacarbazine Review articles on Dacarbazine Articles on Dacarbazine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dacarbazine Images of Dacarbazine Photos of Dacarbazine Podcasts & MP3s on Dacarbazine Videos on Dacarbazine
Evidence Based Medicine
Cochrane Collaboration on Dacarbazine Bandolier on Dacarbazine TRIP on Dacarbazine
Clinical Trials
Ongoing Trials on Dacarbazine at Clinical Trials.gov Trial results on Dacarbazine Clinical Trials on Dacarbazine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dacarbazine NICE Guidance on Dacarbazine NHS PRODIGY Guidance FDA on Dacarbazine CDC on Dacarbazine
Books
Books on Dacarbazine
News
Dacarbazine in the news Be alerted to news on Dacarbazine News trends on Dacarbazine
Commentary
Blogs on Dacarbazine
Definitions
Definitions of Dacarbazine
Patient Resources / Community
Patient resources on Dacarbazine Discussion groups on Dacarbazine Patient Handouts on Dacarbazine Directions to Hospitals Treating Dacarbazine Risk calculators and risk factors for Dacarbazine
Healthcare Provider Resources
Symptoms of Dacarbazine Causes & Risk Factors for Dacarbazine Diagnostic studies for Dacarbazine Treatment of Dacarbazine
Continuing Medical Education (CME)
CME Programs on Dacarbazine
International
Dacarbazine en Espanol Dacarbazine en Francais
Business
Dacarbazine in the Marketplace Patents on Dacarbazine
Experimental / Informatics
List of terms related to Dacarbazine

Overview

Dacarbazine (da-KAR-ba-zeen) (brand names DTIC, DTIC-Dome; also known as DIC or Imidazole Carboxamide) is an antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma and Hodgkin lymphoma. Antineoplastic drugs are drugs which interfere with cell growth and impede the formation of new tissue - in this case, tumor tissue. These drugs are also known as cytotoxic drugs. Dacarbazine belongs to the family of chemicals known as alkylating agents. Dacarbazine is normally administered by injection (a shot) or intravenous infusion (IV) under the immediate supervision of a doctor or nurse.

History

See also: History of cancer chemotherapy

Dacarbazine gained FDA approval in May 1975 as DTIC-Dome. The drug was initially marketed by Bayer.

Side effects

Like many chemotherapy drugs, dacarbazine may have numerous serious side effects, because it interferes with normal cell growth as well as cancer cell growth. Among the most serious possible side effects are birth defects to children conceived or carried during treatment; sterility, possibly permanent; or immune suppression (reduced ability to fight infection or disease). Like most powerful drugs, it may produce more common side effects like nausea, fatigue, headache, etc.

Common uses

As of mid-2006, dacarbazine is commonly used as a single agent in the treatment of metastatic melanoma, and as part of the ABVD chemotherapy regimen to treat Hodgkin lymphoma.

Experimental

Dacarbazine + Oblimersen. In clinical trials for malignant melanoma.

Suppliers

Bayer continues to supply DTIC-Dome. There are also generic versions of dacarbazine available from APP, Bedford, Mayne Pharma and Sicor (Teva).

See also

• Melanoma
• Hodgkin disease
• ABVD
• History of cancer chemotherapy
• Alkylating antineoplastic agent

Sources

• MedLine, U.S. National Institutes of Health, National Library of Medicine, http://www.nlm.nih.gov/medline/
• Cancerweb, http://cancerweb.ncl.ac.uk/cancerweb/
• OncoLink, http://oncolink.upenn.edu/